海藻酸钠-壳聚糖微胶囊膜强度的研究

以乳化/内部凝胶化法制备了海藻酸钠-壳聚糖微胶囊,重点考察了成膜反应过程中影响微胶囊膜强度的几个主要参数,实验发现,壳聚糖分子量低于100000,成膜反应时间高于15min,壳聚糖溶液pH值在6.0左右时制备的微胶囊膜强度较高.初步探讨了海藻酸钠与壳聚糖两种高分子发生聚电解质络合反应的机制.     

壳聚糖溶液pH对载细胞海藻酸钠-壳聚糖微胶囊性能的影响

以激光共聚焦扫描显微镜为研究手段, 原位直观地考察了在不同pH条件下聚电解质膜的络合程度和蛋白扩散情况. 通过分析pH值对微胶囊膜性能的影响规律, 并结合不同种类细胞对环境pH的敏感特性, 确定了制备细胞培养用海藻酸钠-壳聚糖微胶囊的最佳pH值. 结果表明, 当壳聚糖溶液的pH值由3.50增加到6.50, 微胶囊膜的络合深度呈现高-低-高的趋势, 而微胶囊膜的膨胀性能呈现低-高-低的趋势, 模型蛋白通过微囊膜的扩散呈现低-高-低的趋势, 拐点均出现在pH=4.00和5.50处. 结合动物细胞及微生物细胞对环境pH耐受能力的考察, 确定制备微囊化动物细胞时, 微胶囊成膜反应溶液的最佳pH值为5.50; 制备微囊化大肠杆菌时, 反应溶液的最佳pH值为5.00; 制备微囊化酵母菌时, 反应溶液的最佳pH值为4.50.     

肽类药物口服剂型材料及控制释放性能研究Ⅰ.壳聚糖─海藻酸盐微囊对胰岛素的控释作用

应用壳聚糖-海藻酸盐微囊技术制备了一系列胰岛素微囊，并研究了不同反应条件如海藻酸钠浓度、壳聚糖浓度、壳聚糖分子量及壳聚糖溶液pH值对微囊的胰岛素包封率及其释放性能的影响。结果表明，海藻酸钠浓度越高，微囊对胰岛素的包封率越高，在模拟小肠液中释放速率越低；壳聚糖浓度越大，微囊的胰岛素包封率及其在模拟胃液中释放率越高，在模拟肠液中释放达最大值所需时间越长；而随壳聚糖分子量减小，微囊在胃液中释放率增高；壳聚糖溶液pH值的变化对微囊的胰岛素包封率未造成明显影响。     

明胶-海藻酸钙复合膜胶囊萃取Cr2O72-的传质动力学研究

采用胶囊化技术制备三辛胺(TOA)的明胶-海藻酸钙复合膜胶囊,考察其在硫酸介质中萃取Cr2O72-的传质动力学．通过对渗透系数的测定,得出了适于微胶囊萃取的最佳条件:海藻酸钠质量浓度为0.7％,明胶质量浓度为5％-6％,V水／V油=3 :2。     

海藻酸钙凝胶小球与丙烯腈的接枝共聚改性

海藻酸钙水凝胶由天然多糖海藻酸钠与二价钙离子交联形成,具有良好的生物相容,性在药物控制释放等领域得到了广泛的应用。但海藻酸钙水凝胶在大气和电解质溶液中的稳定性较差,常采用与壳聚糖等聚电解质形成复合物的方法加以改善。我们曾利用化学法将醋酸乙烯酯接枝到海藻酸钙     

磁性微胶囊的制备及其药物缓控释性能

用乳液-凝胶法制备了磁性壳聚糖/海藻酸钠微胶囊. 在壳聚糖/海藻酸钠微胶囊中掺入Fe3O4磁性中空球, 使微胶囊具有磁靶向性能. 以头孢拉定作为模型药物研究了载药磁性微胶囊的载药量、包封率及药物缓控释性能等. 结果表明, 提高头孢拉定的初始浓度可以提高载药量, 却不利于提高药物的包封率. 所制备的微胶囊在各种缓冲溶液中长时间内具有显著的缓释效果, 并具有pH 刺激响应释放的性能, 即在模拟胃液中的药物释放率大大降低, 而在模拟体液和肠液中的释放时间大大延长, 可达50 h以上. 另外, 在外加磁场作用下, 微胶囊表现出良好的磁定向运动性能, 为磁靶向药物输送提供基础.     

双重载药多层海藻酸盐-壳聚糖缓释微球的制备及体外释放

采用滴注法将海藻酸钠与钙离子交联,制成负载血管内皮生长因子(VEGF)的藻酸钙核心球,利用层层自组装技术在核心球的表面依次包覆壳聚糖、海藻酸和壳聚糖,壳聚糖中负载万古霉素(VAN),形成多药载药缓控体系.采用正交实验考察海藻酸钠浓度、钙离子浓度及壳聚糖浓度对VEGF和VAN的药物包封率和载药量的影响,优化了制备工艺.采用扫描电子显微镜观察多层微球的表面、截面形貌及粒径,采用傅里叶变换红外光谱检测海藻酸盐与壳聚糖的自组装情况,分别采用酶联免疫吸附(ELISA)双抗体夹心法和紫外分光光度法检测VEGF和VAN的包封率、载药量及体外释放情况.结果表明,海藻酸钠最优浓度为0.04g/mL,氯化钙最优浓度为0.15g/mL,壳聚糖最优浓度为0.01g/mL.微球光滑圆整,均质实心,直径900~1100μm,VEGF的包封率达61.31%,VAN的包封率为3.48%.体外释放实验结果表明,VEGF缓释时间为15.5d,并出现2个释放高峰;VAN缓释时间为4.5d,释药情况平稳持续,无明显突释.双重载药多层包覆微球兼具控制感染和促进血管生成两种潜能,有望应用于组织工程骨的基础研究和临床实践.     

壳聚糖-海藻酸盐纳米粒子的制备及其对BSA的载药与释放特性

带相反电荷的聚电解质在水溶液中能通过静电相互作用自组装形成壳聚糖-海藻酸盐纳米粒。利用动态光散射纳米粒度分析仪考察了钙离子及壳聚糖对粒子粒径的影响。结果表明：钙离子的存在可使粒子粒径从268．5nm降为203．4nm,但随着钙离子含量的继续升高,粒径迅速增大,当钙离子浓度大于0．45g／L时形成凝胶。壳聚糖含量的增加和蛋白的包裹均会使粒径增大。所制备的纳米粒对BSA具有较高的包栽能力,并有一定的缓释作用。当壳聚糖投料量增加时,可使BSA在pH=7．4的PBS中的释放减慢。     

自支撑海藻酸钙水凝胶抗污染过滤膜的制备及截留性能

以聚乙二醇(PEG)为致孔剂制备了自支撑海藻酸钙(CA)水凝胶过滤膜.通过数码照片及扫描电镜观察膜的表面形貌,探讨了膜的力学性能的压缩率、通量与压力的关系.研究了海藻酸钠浓度、致孔剂浓度对纯水通量和溶菌酶(Lyz)截留性能的影响.结果表明,海藻酸钠浓度越低,PEG浓度越高,膜的通量越大,压缩率也越大.膜通量随着跨膜压力的增加呈现先上升后稳定的趋势.Lyz和牛血清蛋白(BSA)溶液的稳定通量分别为纯水通量的89.97%和94.6%,表明海藻酸钙水凝胶过滤膜具有良好的抗蛋白质污染性能.膜对乳化油的过滤通量为纯水通量的93.04%,且截留率高达99.85%.对于不同分子量PEG的截留结果表明,当PEG分子量大于致孔剂的分子量时,截留率达到90%以上.以低分子量PEG400为致孔剂制备的水凝胶过滤膜对染料亮蓝的截留率达到99.75%,表明该水凝胶膜具有作为纳滤膜的前景.     

微囊化海藻酸离子移变凝胶的制备、结构与性能

通过静电脉冲技术制备了海藻酸-壳聚糖-海藻酸(Alginate-Chitosan-Alginate,ACA)微胶囊,红外光谱分析表明,ACA是一种以聚电解质配合物为囊膜,以海藻酸钠离子吸附剂为囊心物的微胶囊型离子吸附体系.扫描电镜测试表明,ACA吸附重金属离子的过程是微胶囊囊内海藻酸凝胶化的过程,其解吸附过程是海藻酸凝胶转变成海藻酸溶液的过程.与传统离子交换树脂相比,ACA对Pb²⁺的吸附具有较高的去除率、很强的富集能力和较低的极限吸附浓度,并且能够被多次重复使用.ACA的离子交换速率比传统离子交换树脂快得多,离子交换过程中,交换离子和吸附剂海藻酸分子的相互扩散大大提高了离子交换速率.     

壳聚糖─海藻酸钠微囊对蛋白质控制释放的研究

采用乳化法制备了可注射用壳聚糖海藻酸钠微囊, 其粒径小于２００ μｍ ,且具有相对较窄的近似高斯分布。牛血清白蛋白作为模型药物在微囊中的包埋率可超过５０ ％ 。通过壳聚糖在海藻酸钠微囊表面的复合,牛血清白蛋白从微囊中的持续释放时间从几个小时延长到半个月以上。     

Degradation of PEG and non-PEG alginate-chitosan microcapsules in different pH environments

Bioencapsulation allows the protection of biologically active substances or cells from the biological environment. As such, bioencapsulation is often used for the delivery of drugs, growth factors and therapeutically useful cells. Depending on the site of implantation, the biocapsules are subjected to different pH environments, which will affect the degradation properties, mechanical properties and swelling behaviour of the biocapsules. As such, the encapsulation material plays an important role in the long term stability and performance of the biocapsules in vivo. In this study, five types of encapsulation materials were investigated: (i) alginate (A), (ii) alginate-chitosan (AC), (iii) alginate-chitosan-alginate (ACA), (iv) alginate-chitosan-polyethylene glycol (PEG) (ACP) and (v) alginate-chitosan-polyethylene glycol (PEG)-alginate (ACPA). Degradation studies were carried out by immersing the microcapsules in solutions of different pH values to investigate the role of the material as well as the number of encapsulation layers in maintaining the stability of the microcapsules in the different pH environments. Compression testing indicated that even with the presence of PEG on the surface membrane, there was not much difference in mechanical strength between ACA and ACPA microcapsules. However, the use of PEG did affect the weight change of the ACPA microcapsules when immersed in water and three different pH solutions. For the swelling test, the ACPA microcapsules showed a lower water uptake than ACA microcapsules. For degradation, the presence of PEG led to a lower increase in weight change compared to non-PEG chitosan microcapsules. Hence, the study revealed that PEG influenced the integrity of the surface membrane and not the mechanical strength of the microcapsules. With the inclusion of PEG, the interpenetrating network on the surface membrane would be further reinforced. As such, the addition of PEG to the alginate-chitosan microcapsules led to protection against an acidic environment, whilst the number of coating layers only influences the swelling properties and not the degradation and Young’s modulus of the microcapsules.     

Studies in the development of nateglinide loaded calcium alginate and chitosan coated calcium alginate beads

Nateglinide loaded alginate-chitosan beads were prepared by ionic gelation method for controlling the drug release by using various combinations of chitosan and Ca2+ as cation and alginate as anion. IR spectrometry, scanning electron microscopy, differential scanning calorimetry and X-ray powder diffractometry were used to investigate the physicochemical characteristics of the drug in the bead formulations. The calcium content in beads was determined by atomic absorption spectroscopy. The swelling ability of the beads in different media (pH 1.2, 4.5, 6.8) has been found to be dependent on the presence of polyelectrolyte complex of the beads and the pH of the media. The ability to release the Nateglinide was examined as a function of chitosan and calcium chloride content in the gelation medium. It is evident that the rate of drug release and its kinetics could be controlled by changing the chitosan and the calcium chloride concentrations. Calcium alginate beads released more than 95% of drug with in 8 h; whereas coated beads sustained the drug release and released only 75-80% of drug. The drug release mechanism analyzed indicates that the release follows either "anomalous transport" or "case-II transport".     

Core‐shell structure microcapsules with dual pH‐responsive drug release function

We report dual pH‐responsive microcapsules manufactured by combining electrostatic droplets (ESD) and microfluidic droplets (MFD) techniques to produce monodisperse core (alginate)‐shell (chitosan) structure with dual pH‐responsive drug release function. The fabricated core‐shell microcapsules were size controllable by tuning the synthesis parameters of the ESD and MFD systems, and were responsive in both acidic and alkaline environment, We used two model drugs (ampicillin loaded in the chitosan shell and diclofenac loaded in the alginate core) for drug delivery study. The results show that core‐shell structure microcapsules have better drug release efficiency than respective core or shell particles. A biocompatibility test showed that the core‐shell structure microcapsules presented positive cell viability (above 80%) when evaluated by the 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assay. The results indicate that the synthesized core‐shell microcapsules were a potential candidate of dual‐drug carriers.     

Chitosan–Alginate Microcapsules for Oral Delivery of Egg Yolk Immunoglobulin (IgY): Effects of Chitosan Concentration

In our previous study, chitosan–alginate microcapsules were developed to protect egg yolk immunoglobulin (IgY) from gastric inactivation. The present study was undertaken to determine the effect of chitosan concentration (0–0.8%; w/v) on various properties of the microcapsules in order to produce the optimum chitosan–alginate microcapsules for use in the oral delivery of IgY. The properties investigated included microcapsule morphology, loading capacity for IgY (expressed as the IgY loading percentage, w/w, of microcapsules), encapsulation efficiency (EE%), in vitro gastroresistance, and IgY release. IgY loading percentage and EE% were both highest at 0.2% (w/v) chitosan, and, above this level, further increases were not observed. The stability of IgY in simulated gastric fluid (pH 1.2) was significantly improved by encapsulation in alginate microcapsules (IgY retained 43.5% of its activity) and was further improved by including chitosan at any of the chitosan concentrations assessed (IgY retained an average of 69.4% activity) although there was no difference in protection of gastric inactivation among concentrations of chitosan varying from 0.05% to 0.8% (w/v). Higher chitosan concentrations (i.e., ≥0.2%; w/v) prolonged the release of IgY from the microcapsules during simulated intestinal fluid incubation (pH 6.8). However, above the 0.2% (w/v) level, no significant differences were observed. We conclude that the optimum chitosan concentration for microencapsulation is 0.2% (w/v).     

Composite microparticle drug delivery systems based on chitosan, alginate and pectin with improved pH-sensitive drug release property

Composite microparticle drug delivery systems based on chitosan, alginate and pectin with improved pH sensitivity were developed for oral delivery of protein drugs, using bovine serum albumin (BSA) as a model drug. The composite drug-loaded microparticles with a mean particle size less than 200 μm were prepared by a convenient shredding method. Since the microparticles were formed by tripolyphosphate cross-linking, electrostatic complexation by alginate and/or pectin, as well as ionotropic gelation with calcium ions, the microparticles exhibited an improved pH-sensitive drug release property. The in vitro drug release behaviors of the microparticles were studied in simulated gastric (pH 1.2 and pH 5.0), intestinal (pH 7.4) and colonic (pH 6.0 and pH 6.8 with enzyme) media. For the composite microparticles with suitable compositions, the releases of BSA at pH 1.2 and pH 5.0 could be effectively sustained, while the releases at pH 7.4, pH 6.8 and pH 6.0 increased significantly, especially in the presence of pectinase. These results clearly suggested that the microparticles had potential for site-specific protein drug delivery through oral administration.